奥泰生物(688606) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 reached RMB 86,979.22 million, an increase of 15.25% compared to the previous year[3] - Net profit attributable to shareholders of the parent company was RMB 30,368.83 million, reflecting a growth of 68.18% year-on-year[5] - The profit margin before non-recurring items increased to RMB 23,937.15 million, up 62.92% from the previous year[5] - Basic earnings per share rose to RMB 3.83, a 67.98% increase compared to the same period last year[3] - The weighted average return on equity improved to 7.84%, an increase of 3.32 percentage points[3] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 418,645.82 million, a 1.71% increase from the beginning of the period[4] - Shareholders' equity attributable to the parent company was RMB 388,496.46 million, up 1.51% from the start of the period[4] Operational Focus - The company maintained a strong focus on R&D in the POCT sector, ensuring new product launches every month[6] - The increase in operating profit and total profit was primarily driven by revenue growth and cost control measures[8] - The company emphasizes internal management improvements and production automation to enhance efficiency and quality[6]